Fig 7.

Depletion of ATG5 and beclin-1 by siRNA treatments impairs the antiviral activity of RNase L. (A and D) Effects of siRNA against ATG5 mRNA and beclin-1 (bec) mRNA, respectively, in WT and Rnasel^−/− MEF as determined in immunoblots in comparison to β-actin levels. Ctr, nontargeted siRNA control. (B and E) After siRNA or control (ctr) siRNA treatments, cells were infected with EMCV (MOI = 0.05). Viral yields were measured at 8 h postinfection. (C and F) Increases in the viral titers presented in panels B and E were determined by comparing viral yields between siRNA- and control siRNA-treated cells. Values and SD (error bars) were determined from three biological replicates. **, P < 0.01; ***, P < 0.001; ns, not significant.